Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 2955-2961

  Tao, Tao ^a   Durbin, Anna P ^a   Whitehead, Stephen S ^a   Davoodi, Fatemah ^a   Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HN PROTEIN; HYBRID PROTEIN; PARAINFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARTICLE; CYTOPATHOGENIC EFFECT; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN BINDING; VACCINATION; VIRUS ENVELOPE; VIRUS RECOMBINATION; VIRUS TYPING;

EID: 0031954687     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.2955-2961.1998     Document Type: Article

References (38)

1. Belshe, R. B., and F. K. Hissom. 1982. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol. 10:235-242.
2. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus (RSV) from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
3. Byrappa, S., D. K. Gavin, and K. C. Gupta. 1995. A highly efficient procedure for site-specific mutagenesis of full-length plasmids using Vent DNA polymerase. Genome Res. 5:404-407.
4. Calain, P., and L. Roux. 1993. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67:4822-4830.
5. Collins, P. L., R. M. Chanock, and K. McIntosh 1996. Parainfluenza viruses, p. 1205-1243. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed, vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
6. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567.
7. Crowe, J. E., Jr., P. L. Collins, R. M. Chanock, and B. R. Murphy. 1997. Vaccines against respiratory syncytial virus and parainfluenza virus type 3, p. 711-725. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
8. Durbin, A. P., S. L. Hall, J. W. Siew, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1997. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235:323-332.
9. Durbin, A. P., J. W. Siew, B. R. Murphy, and P. L. Collins. 1997. Minimum protein requirements for transcription and RNA replication of a mini-genome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 234:74-78.
10. Frank, A. L., R. B. Couch, C. A. Griffis, and B. D. Baxter. 1979. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J. Clin. Microbiol. 10:32-36.
11. Galinski, M. S. 1991. Paramyxoviridae: transcription and replication. Adv. Virus Res. 39:129-162.
12. Galinski, M. S., M. A. Mink, and M. W. Pons. 1988. Molecular cloning and sequence analysis of the human parainfluenza 3 virus gene encoding the L protein. Virology 165:499-510.
13. Galinski, M. S., R. M. Troy, and A. K. Banerjee. 1992. RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3. Virology 186:543-550.
14. Garcin, D., T. Pelet, P. Calain, L. Roux, J. Curran, and D. Kolakofsky. 1995. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 14:6087-6094.
15. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184.
16. Hoffman, M. A., and A. K. Banerjee. 1997. An infectious clone of human parainfluenza virus type 3. J. Virol. 71:4272-4277.
17. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819.
18. Karron, R. A., P. F. Wright, S. L. Hall, M. Makhene, J. Thompson, B. A. Burns, S. Tollefson, M. C. Steinhoff, M. H. Wilson, D. O. Harris, M. L. Clements, and B. R. Murphy. 1995. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. 171:1107-1114.
19. Karron, R. A., P. F. Wright, F. K. Newman, M. Makhene, J. Thompson, R. Samorodin, M. H. Wilson, E. L. Anderson, M. L. Clements, B. R. Murphy, and R. B. Belshe. 1995. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1445-1450.
20. Kato, A., Y. Sakai, T. Shioda, T. Kondo, M. Nakanishi, and Y. Nagai. 1996. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1:569-579.
21. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92:4477-4481.
22. Marx, A., T. J. Torok, R. C. Holman, M. J. Clarke, and L. J. Anderson. 1997. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176:1423-1427.
23. Mbiguino, A., and J. Menezes. 1991. Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J. Virol. Methods 31:161-170.
24. Mebatsion, T., M. Konig, and K. K. Conzelmann. 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 84:941-951.
25. Murphy, B. R., G. A. Prince, P. L. Collins, K. Van Wyke Coelingh, R. A. Olmsted, M. K. Spriggs, R. H. Parrott, H. W. Kim, C. D. Brandt, and R. M. Chanock. 1988. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11:1-15.
26. Murphy, B. R., D. D. Richman, E. G. Chalhub, C. P. Uhlendorf, S. Baron, and R. M. Chanock. 1975. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect. Immun. 12:62-68.
27. Naim, H. Y., P. Speilhofer, D. Christiansen, and M. A. Billeter. 1997. Properties of constructed measles virus chimeras, p. 102. In Emergence and re-emergence of negative strand viruses, Tenth International Conference on Negative Stand Viruses, Dublin, Ireland.
28. Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M. Huber, C. Dotsch, G. Christiansen, and M. A. Billeter. 1995. Rescue of measles viruses from cloned DNA. EMBO J. 14:5773-5784.
29. Schlender, J., J. J. Schnorr, P. Spielhoffer, T. Cathomen, R. Cattaneo, M. A. Billeter, V. ter Meulen, and S. Schneider-Schaulies. 1996. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc. Natl. Acad. Sci. USA 93:13194-13199.
30. Schnell, M. J., T. Mebatsion, and K. K. Conzelmann. 1994. Infectious rabies viruses from cloned cDNA. EMBO J. 13:4195-4203.
31. Schnitzer, T. J., C. Dickson, and R. A. Weiss. 1979. Morphological and biochemical characterization of viral particles produces by the tsO45 mutant of vesicular stomatitis virus at restrictive temperature. J. Virol 29:185-195.
32. Skiadopolous, M. H., A. P. Durbin, J. M. Tatem, S. Wu, M. Paschalis, T. Tao, P. L. Collins, and B. R. Murphy. 1998. Three amino acid substitutions in the L protein of the human parainfluenza type 3 cp45 Live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72:1762-1768.
33. Spriggs, M. K., and P. L. Collins. 1986. Sequence analysis of the P and C protein genes of human parainfluenza virus type 3: pattern of amino acid sequence homology among paramyxovirus proteins. J. Gen. Virol. 67:2705-2719.
34. Stokes, A., E. L. Tierney, B. R. Murphy, and S. L. Hall. 1992. The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res. 25:91-103. (Erratum, 27:96, 1993)
35. Tanabayashi, K., and R. W. Compans. 1996. Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion. J. Virol. 70:6112-6118.
36. van Wyke Coelingh, K. L., C. Winter, and B. R. Murphy. 1985. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 143:569-582.
37. Whelan, S. P., L. A. Ball, J. N. Barr, and G. T. Wertz. 1995. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA 92:8388-8392.
38. Wyatt, L. S., B. Moss, and S. Rozenblatt. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.